Skip to main content

Advertisement

SpringerLink
Log in

Mean platelet volume as a potential biomarker for survival outcomes in ovarian clear cell carcinoma

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Objective

This study aimed to explore the prognostic value of mean platelet volume (MPV) in patients with ovarian clear cell carcinoma (OCCC) and evaluate the predictive performance of a random forest model incorporating MPV and other key clinicopathological factors.

Methods

A total of 204 patients with OCCC treated between January 2004 and December 2019 were retrospectively analyzed. Clinicopathological characteristics and preoperative laboratory data were collected, and survival outcomes were evaluated using the Kaplan–Meier method and Cox proportional hazards models. An optimal MPV cutoff was determined by receiver operating characteristic (ROC) curve analysis. A random forest model was then constructed using the identified independent prognostic factors, and its predictive performance was evaluated.

Results

The ROC analysis identified 9.3 fL as the MPV cutoff value for predicting 2-year survival. The MPV-low group had lower 5-year overall survival and progression-free survival rates than the MPV-high group (p = 0.003 and p = 0.034, respectively). High MPV emerged as an independent prognostic factor (p = 0.006). The random forest model, incorporating the FIGO stage, residual tumors, peritoneal cytology, and MPV, demonstrated robust predictive performance (area under the curve: 0.905).

Conclusion

MPV is a promising prognostic indicator in OCCC. Lower MPV correlated with worse survival rates, advocating its potential utility in refining patient management strategies. The commendable predictive performance of the random forest model, integrating MPV and other significant prognostic factors, suggests a pathway toward enhanced survival prediction, thereby warranting further research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Shu CA et al (2015) Ovarian clear cell carcinoma, outcomes by stage: the MSK experience. Gynecol Oncol 139(2):236–241

    Article  PubMed  PubMed Central  Google Scholar 

  2. del Carmen MG, Birrer M, Schorge JO (2012) Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol 126(3):481–490

    Article  PubMed  Google Scholar 

  3. Bookman MA et al (2014) Better therapeutic trials in ovarian cancer. J Natl Cancer Inst 106(4):dju029

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tan DS, Kaye S (2007) Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 60(4):355–360

    Article  CAS  PubMed  Google Scholar 

  5. Sugiyama T et al (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88(11):2584–2589

    Article  CAS  PubMed  Google Scholar 

  6. Chan JK et al (2008) Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109(3):370–376

    Article  PubMed  Google Scholar 

  7. Tammela J et al (1998) Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol 19(5):438–440

    CAS  PubMed  Google Scholar 

  8. Bancroft AJ et al (2000) Mean platelet volume is a useful parameter: a reproducible routine method using a modified coulter thrombocytometer. Platelets 11(7):379–387

    Article  CAS  PubMed  Google Scholar 

  9. Repsold L, Joubert AM (2021) Platelet function, role in thrombosis, inflammation, and consequences in chronic myeloproliferative disorders. Cells 10(11):3034

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11(2):123–134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wojtukiewicz MZ et al (2017) Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev 36(2):249–262

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Takagi S et al (2013) Platelets promote tumor growth and metastasis via direct interaction between aggrus/podoplanin and CLEC-2. PLoS ONE 8(8):e73609

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kharel S et al (2022) Prognostic significance of mean platelet volume in patients with lung cancer: a meta-analysis. J Int Med Res 50(3):3000605221084874

    Article  CAS  PubMed  Google Scholar 

  14. Li N et al (2017) Elevated mean platelet volume predicts poor prognosis in colorectal cancer. Sci Rep 7(1):10261

    Article  PubMed  PubMed Central  Google Scholar 

  15. Omar M et al (2018) Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. Clin Respir J 12(3):922–929

    Article  CAS  PubMed  Google Scholar 

  16. Yagyu T et al (2021) Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer. BMC Surg 21(1):8

    Article  PubMed  PubMed Central  Google Scholar 

  17. Delago D et al (2020) The decreased mean platelet volume is associated with poor prognosis in patients with oropharyngeal cancer treated with radiotherapy. Radiat Oncol. https://doi.org/10.1186/s13014-020-01702-4

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kemal Y et al (2014) Mean platelet volume could be a useful biomarker for monitoring epithelial ovarian cancer. J Obstet Gynaecol 34(6):515–518

    Article  CAS  PubMed  Google Scholar 

  19. Yilmaz E et al (2017) MPV, NLR, and platelet count: new hematologic markers in diagnosis of malignant ovarian tumor. Eur J Gynaecol Oncol 38(3):346–349

    CAS  PubMed  Google Scholar 

  20. Zhu C et al (2021) Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. BMC Cancer 21(1):322

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kimura N et al (2020) Optimal preoperative multidisciplinary treatment in borderline resectable pancreatic cancer. Cancers (Basel) 13(1):1–36

    Article  Google Scholar 

  22. Schnack TH et al (2016) Demographic clinical and prognostic factors of primary ovarian adenocarcinomas of serous and clear cell histology-a comparative study. Int J Gynecol Cancer 26(1):82–90

    Article  PubMed  Google Scholar 

  23. Tang HS et al (2008) Clear cell carcinoma of the ovary: clinicopathologic features and outcomes in a Chinese cohort. Medicine 97(21):e10881

    Article  Google Scholar 

  24. Li N et al (2017) Elevated mean platelet volume predicts poor prognosis in colorectal cancer. Sci Rep. https://doi.org/10.1038/s41598-017-11053-y

    Article  PubMed  PubMed Central  Google Scholar 

  25. Shen XM et al (2016) Mean platelet volume provides beneficial diagnostic and prognostic information for patients with resectable gastric cancer. Oncol Lett 12(4):2501–2506

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lev EI (2016) Immature platelets: clinical relevance and research perspectives. Circulation 134(14):987–988

    Article  PubMed  Google Scholar 

  27. Couldwell G, Machlus KR (2019) Modulation of megakaryopoiesis and platelet production during inflammation. Thromb Res 179:114–120

    Article  CAS  PubMed  Google Scholar 

  28. Korniluk A et al (2019) Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediat Inflamm 2019:9213074

    Article  Google Scholar 

  29. Yin M et al (2022) Impact of adjuvant chemotherapy on FIGO stage I ovarian clear cell carcinoma: a systematic review and meta-analysis. Front Oncol 12:811638

    Article  PubMed  PubMed Central  Google Scholar 

  30. Iida Y et al (2021) Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int J Gynecol Cancer 31(4):605–616

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS), grant number 22K16876. We express our sincere gratitude to JSPS for their generous financial support which made this research possible.

Funding

This study was funded by Japan Society for the Promotion of Science (JSPS), 22K16876, Nobuhisa Yoshikawa.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-Cho 65, Showa-Ku, Nagoya, 466-8550, Japan

    Nobuhisa Yoshikawa, Tetsuya Matsukawa, Satomi Hattori, Shohei Iyoshi, Kosuke Yoshida, Masato Yoshihara, Satoshi Tamauchi, Yusuke Shimizu, Yoshiki Ikeda, Akira Yokoi, Kaoru Niimi & Hiroaki Kajiyama

  2. Department of Obstetrics and Gynecology, Toyohashi Municipal Hospital, Toyohashi, Japan

    Michiyasu Kawai

Authors
  1. Nobuhisa Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuya Matsukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satomi Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shohei Iyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kosuke Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masato Yoshihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satoshi Tamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yusuke Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshiki Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akira Yokoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kaoru Niimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Michiyasu Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hiroaki Kajiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NY: data analysis, conceptualization, interpretation, and drafting of manuscript. TM, HS, SI, KY, MY, ST, AY, YI, YS, KN, KM: data collection. HK: supervision, revising the manuscript.

Corresponding author

Correspondence to Nobuhisa Yoshikawa.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Institutional Review Board statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Nagoya University Hospital (2006–0357). Patient consent was waived because data collection was retrospective.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

10147_2023_2417_MOESM1_ESM.pdf

Supplementary file1 Supplemental Fig. 1: Comparison of mean MPV values: healthy individuals, patients with endometriosis, and patients with OCCC. Patients with endometriosis had a significantly higher mean MPV than patients with OCCC (p < 0.05). (PDF 59 KB)

10147_2023_2417_MOESM2_ESM.pdf

Supplementary file2 Supplemental Fig. 2: Comparison of MPV values across FIGO stages I, II, III, and IV. No statistically significant difference was detected between the MPV values of stages I–II and III–IV. (PDF 59 KB)

10147_2023_2417_MOESM3_ESM.pdf

Supplementary file3 Supplemental Fig. 3: Kaplan–-Meier survival curves of OCCC patients with ovarian clear cell carcinoma (OCCC) stratified by postoperative day 7 MPV. The prognosis significantly varied based on the 8.8 fL cutoff (p = 0.0291). (PDF 26 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshikawa, N., Matsukawa, T., Hattori, S. et al. Mean platelet volume as a potential biomarker for survival outcomes in ovarian clear cell carcinoma. Int J Clin Oncol 28, 1680–1689 (2023). https://doi.org/10.1007/s10147-023-02417-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-023-02417-8

Keywords

Search

Navigation